Menu
Currently, many complex diseases are detected too late in their progression based on symptoms that can be misleading. Ariel goes beyond symptoms using genetics to provide valuable information to clarify risk and guide a personalized approach to the early detection and treatment of complex diseases. Our reports are tailored to each patient, integrating patient reported outcomes, environmental and medical history into the interpretation of the genetic data.
Curated Single Nucleotide Polymorphism (SNP) Genotyping
Ariel uses pre-defined SNPs with known effects so that the impact can immediately be integrated into complex disease models and the analysis process is not slowed by exploring the possible impact of rare genetic variants of unknown significance (VUS). This approach optimizes speed and efficiency of the system as a screening tool with the recognition that additional genetic testing may be required to discover rare or complex genetic variants that are not commonly part of established disease models.
Order Remotely
Ariel’s SNaP-Shot™ panels can be ordered remotely for patients and testing can be done in the privacy of their home using a cheek swab test. Ariel’s tests can be ordered by a licensed provider and the direct pay model ensures complete transparency into pricing.
What ARIEL offers you, the physician:
Unravel complex conditions with the help of integration of health information backed by genetics. Ariel uses comprehensive genetic testing to understand and interpret risk factors for each patient. In addition to traditional Mendelian variants, Ariel reports disease modifying and complex genetic variants, some of which can influence biomarker interpretation and drug response.
Our platform provides you with clinical considerations according to guidelines Our forward thinking team monitors research on re-classification of variants or discovery of new variants and integrates this new information into our platform to push relevant updates to you for each patient over time.
Our reports are tailored to each patient, integrating patient reported outcomes, environmental and medical history (including family history) into the interpretation of their genetic data.
Our platform uses high quality array technology in a CLIA-certified laboratory with layers of QC to confirm accuracy for reporting.
SNaP-Shot™ is a Precision Medicine tool. SNaP-Shot™ Reports are based on the analysis of limited sets of patient genetic (DNA) variants relevant to signs and symptoms of human disease. The data is transformed into clinically relevant information by combining an individual’s genetic information with their relevant health histories, lifestyle information and biomarkers using disease models linked to expert clinical decision support (CDS) systems. This new patient-specific information is designed
to help clinicians with (a) risk assessment, (b) differential diagnosis, (c) treatment selection, (d) prognosis and/or (e) management plans. HIPAA-compliant Reports are available to healthcare providers and the patient. Reports can be updated over time as the patient’s condition and biomarkers change, as new information becomes available or new medical advances are published.
A genotyping-array test of over 60 genetic variants related to the risk for pancreatitis, celiac disease, gallstones, and hypertriglyceridemia. Also includes a polygenic risk score (PRS) for type 2 diabetes mellitus.
ABCG8, APOA5, APOB, CASR, CFTR, CLDN2, CTRC, GGT1, HLA-DQA1, HLA-DQB1, LPL, PRSS1, PRSS1-PRSS2, SLC10A2, SLC26A9 and SPINK1.
A screening test that identifies high-risk individuals (HRI) who may benefit from pancreatic cancer (PC) surveillance by:
(A) Determining genetic risk factors and incorporating these to their risk status and cancer biomarker profile.
(B) Improving interpretation of new- onset diabetes (NOD) caused by PC. 1, 2
(C) Assessing CA 19-9-related genetic variants (FUT2/FUT3) to help interpret laboratory results.
Pancreatic Cancer Biomarker and Risk SNaP-Shot TM
is $299. Pharmacogenomic SNaP-Shot can be added on for $150.
An affordable clinical pharmacogenomics test and interpretation service that helps identify how patients are likely to respond to a medication or a specific medication dose. By analyzing genetic variants from 27 genes, Pharmacogenomics SNaP-Shot™ provides genetic insights to match appropriate medication and dosage to patients. It can also help avoid adverse drug events that are associated with specific genetic variants. Pharmacogenomics SNaP-Shot™ covers more than 125 medications used to treat a wide range of medical conditions.
ABCG2, BCHE, CACNA1S, COMT, CYP2B6, CYP2C, CYP2C19, CYP2C9, CYP2D6, CYP3A5, CYP4F2, DPYD, HLA-A,
HLA-B, HLA-DQA1, HLA-DRB1, MT-RNR1, MTHFR, NAT1, NAT2,
NUDT15, OPRM1, RYR1, SLCO1B1, TPMT, UGT1A1, & VKORC1
Please note:
$249 for Pharmacogenomics SNaP-Shot™
After the order has been placed, your patient will receive an email invitation to complete registration for testing.
A DNA collection kit will be shipped to your patient’s home. They will collect their DNA sample and send it back to us for analysis.
You will receive an email notification letting you know that the genetic report is ready to review. You will be able to review the report online.
An emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.
For Pancreatitis SNaP-Shot™:
Identifying the underlying biological causes of your patient’s pancreatitis symptoms can help direct therapy and guide medical management specific to the patient’s disease process. For example, genetic conditions such as hereditary pancreatitis and cystic fibrosis can both increase the risk of pancreatitis, but involve different treatments and clinical considerations. Early detection of the cause or causes of the disease process may prevent extensive diagnostic evaluations, delayed diagnosis and more severe end-stage disease.
For Pharmacogenomics SNaP-Shot™:
A person’s genetic variants can impact how they will respond to medications (pharmacogenomics, PGx). PGx data can help you identify patients who are more likely to respond to a medication or a specific medication dose. It can also help patients avoid adverse drug events that are associated with specific genetic variants.
For Pancreatic Cancer SNaP-Shot™:
A genotype based test to screen for risk and support the early detection of pancreatic cancer (combining clinical, environmental and genetic risk factors such as polygenic risk scores and familial cancer variants to determine current risk of an occult cancer and to calibrate the level of CA 19-9 and CEA as biomarkers based on FUT 2/FUT3 genetics), and support management in the event of the early diagnosis of pancreatic cancer including genetic effects on biomarker levels (CA 19-9 and CEA), chemotherapy pharmacogenetics (PGx e.g. 5-FU, Folfirinox) pain and nausea PGx.”
SNaP-Shot™ genetic analysis goes beyond genetics to incorporate genetic testing, patient medical and family history, patient biomarkers, and up-to-date management considerations to provide a comprehensive and actionable precision medicine report.
Pancreatitis SNaP-Shot™ tests for predisposition to both Mendelian (monogenic) and complex (multifactorial) forms of disease. A minority of pancreatitis patients have a monogenic cause of disease. Therefore, testing for predisposing risk variants in addition to monogenic disease variants assures a complete picture of known genetic predisposition.
Pancreatic Cancer SNap-Shot™: A genotype based test to screen for risk and support the early detection of pancreatic cancer (combining clinical, environmental and genetic risk factors such as polygenic risk scores and familial cancer variants to determine current risk of an occult cancer and to calibrate the level of CA 19-9 and CEA as biomarkers based on FUT 2/FUT3 genetics), and support management in the event of the early diagnosis of pancreatic cancer including genetic effects on biomarker levels (CA 19-9 and CEA), chemotherapy pharmacogenetics (PGx e.g. 5-FU, Folfirinox) pain and nausea PGx.”
Pharmacogenomics SNaP-Shot™: is an affordable clinical pharmacogenomics (PGx) test and interpretation service that helps identify how patients are likely to respond to a medication or a specific medication dose. By analyzing genetic variants from 27 genes, Ariel SNaP-Shot™ provides genetic insights to match appropriate medication and dosage to patients. It can also help avoid adverse drug events that are associated with specific genetic variants. Pharmacogenomics SNaP-Shot™ covers more than 125 medications used to treat a wide range of medical conditions.
Please contact info@arielmedicine.com or 844-692-7435 to request a sample report.
Ariel is committed to a streamlined and convenient ordering and results disclosure process:
A new collection kit will be sent to the patient.
Please tell your patient to expect an email from Ariel. Once you place an order in the secure portal, Ariel will send your patient a ‘Welcome’ email with a link to Ariel’s secure patient portal to register. The patient can follow the instructions in their email to register in Ariel’s online portal, provide payment information, complete the informed consents, and their registration profile. Once the registration forms are complete, Ariel ships a DNA testing kit to the patient’s preferred shipping address. The Ariel test kit includes all materials and resources necessary to support the patient in collecting and returning their sample for testing.
No, Ariel does not offer genetic counseling services.
The turnaround time for test results is 4-6 weeks.
Direct pay model overcomes the traditional barriers of prior authorizations, medical record requests, letters of medical necessity and insurance denials.
If you still have questions, we would love to answer them. Request a quick call with our team and we’ll be in touch.
